Laboratory for Immunomonitoring in Oncology (L.I.O)

Head of platform
Pr. Nathalie Chaput

Contact :
Tel.: + 33 (0)1 42 11 37 18

Send an email
Frise Banner: 
Laboratory for Immunomonitoring in Oncology (L.I.O)

Laboratory for immunomonitoring in oncology (L.I.O)

The L.I.O forms part of the CNRS (National Scientific Research Centre) UMS 3655 group & INSERM US23 AMMICa coordinated by Professor Jean-Yves Scoazec. This laboratory is specialised in the evaluation of immunological profiles and testing of immune cell populations in the context of  the administration of immunomodulating therapeutic agents (inhibitors of immune check-points, monoclonal antibody agonists, cytokines etc.)

Its main roles are:

  • To provide a dynamic exploration of the immune system in patients receiving immunomodulating agents in the context of clinical research trials.   
  • To facilitate innovation in immuno-oncology and its transfer to the clinical situation (R&D).

This laboratory, incorporated in a hospital structure, aims to develop and validate biomarkers employed in patient selection and help to identify potential combinations of therapeutic agents.

The L.I.O has validated 12 cell panels 10 colours in whole blood flow cytometry, in order to be able to follow most immune cell populations qualitatively and quantitatively. We are also setting up several panels in order to quantify and phenotype these populations in patient tumour tissue.

At present immunomonitoring techniques encounter various problems: reproducibility, and inter-laboratory harmonisation of procedures. These problems make it difficult to develop reliable and clinically useful immunological markers. 
In order to improve reproducibility and to harmonise methods, we have collaborated with the Pitié Salpêtrière Hospital Biotherapy department and Beckman Coulter® to produce these panels in a dried preparation, (DuraClone®). This presentation is stable over a long period without requiring refrigeration and makes the preparation of samples simpler and more rapid. Finally, it reduces the variability of longitudinal studies and/or those carried out on several sites. These advantages make it possible to carry out studies on whole fresh blood (only 100µl of whole blood per assay). This should increase the probability of identifying relevant, reliable and clinically useful immunological markers.     

Current L.I.O immunomonitoring protocols

Department of oncological medicine

  • Dermatology department       
    • MELIPIRX (Phase I Academic)
    • GOLD  (Academic Clinical Research)
    • COMBAT (Phase I Commercial)
  • Thoracic pathology department
    • Dex² (Phase II academic)
    • GEFTREM (Phase I academic)
    • MSN (Academic Clinical Research)
  • Haematology Department
    • LMMC-Treg (Academic Clinical Research)

DITEP (Department for early clinical trials)

  • ARGNX (Phase I Commercial)

Paediatrics Department

  • LTi-GD2 (Phase I Academic)

R&D

  • Collaboration with Cytune Pharma® on the development of Hyper-IL-15
Catégorie de la page: